Browse by Medical Category
Accepting New Patients
Go To Programs
Go To Programs
Go To Specialties
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
A Massachusetts General Hospital research team has found a surprising potential solution to a persistent clinical problem – the healing of chronic wounds. The researchers report that application of mature B lymphocytes – best known for producing antibodies – greatly accelerated the healing of acute and chronic wounds in both diabetic and nondiabetic mice.
A consortium of academic and industry organizations led by a team from the MGH Vaccine and Immunotherapy Center has launched a new effort to develop an entirely new type of vaccine against Q fever.
An approach developed by MGH investigators may provide a solution to the limitations that have kept pancreatic islet transplantation from meeting its promise as a cure for type 1 diabetes.
Inspired by his wife's memory, Jeffrey Gelfand, MD, and his MGH colleagues set out to create a vaccine to attack tumors in patients already diagnosed with cancer.
A novel approach to cancer immunotherapy may provide a cost-effective weapon against some of the most deadly tumors, including ovarian cancer and mesothelioma. A protein engineered by MGH investigators to combine a molecule targeting a tumor antigen with an immune-function stimuating protein prolonged survival in animal models of both tumors.
New research indicates that using a particular laser to pre-treat the site of a flu shot may boost the body’s immune response against influenza.
Pretreating the site of intradermal vaccination – vaccine delivered into the skin rather than to muscles beneath the skin – with a particular wavelength of laser light may substantially improve vaccine effectiveness without the adverse effects of chemical additives currently used to boost vaccine efficacy.
The Vaccine and Immunotherapy Center at the MGH (VIC), has joined with 24 other institutions as part of the first-ever JDRF Encapsulation Consortium in the fight against type 1 diabetes.
The Vaccine and Immunotherapy Center at Massachusetts General Hospital (VIC), has joined with 24 other institutions as part of the first-ever JDRF Encapsulation Consortium in the fight against type 1 diabetes
The Vaccine & Immunotherapy Center (VIC) at the MGH is committed to projects that accelerate vaccine and immunotherapy development, including those dedicated to finding improved treatment options for people with Type 1 diabetes, an autoimmune disease in which a person’s pancreas stops producing insulin.
A newly created consortium plans to change the future of vaccine research.
MGH Hotline 1.23.09
The MGH is a hub of scientific research and discovery, but translating these breakthroughs into commercial applications can be a challenging and sometimes confusing process.
The Medicine Innovation Program grants supports and provides opportunities to advance innovations in health care delivery within the Department of Medicine at Massachusetts General Hospital.
Back to Top